<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10088">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00693498</url>
  </required_header>
  <id_info>
    <org_study_id>24518</org_study_id>
    <nct_id>NCT00693498</nct_id>
  </id_info>
  <brief_title>Washed Versus Standard Blood Cell Transfusions in Pediatric Open Heart Surgery</brief_title>
  <official_title>Standard vs. Washed Blood Cell Transfusions in Pediatric Cardiac Surgery: Impact on Post-operative Inflammation as Evidenced by the IL-6 to IL-10 Ratio.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Children having open heart surgery to repair congenital heart defects
      demonstrate a large inflammatory response to the heart-lung machine and to surgery itself.
      In general, the more intense their inflammatory response, the more critically ill they are
      following surgery. These children routinely require large numbers of blood transfusions
      during and following surgery as part of their medical management that adds to their
      heightened inflammatory state. Whether additional steps to &quot;wash&quot; blood products and remove
      the substances contributing to post-transfusion inflammation will limit this response, and
      improve the health of children following open heart surgery, remains to be studied.

      Aims: To compare the inflammatory response in children having open heart surgery who receive
      washed versus unwashed blood transfusions.

      Methods: We will randomly assign children having open heart surgery to one of two groups:
      group 1 will receive blood transfusions per the current standard of care, group 2 will
      receive blood transfusions that have been washed in addition to the current standard of
      care. We will then use blood tests to measure the inflammatory response in children of each
      group. We will compare the results to determine whether washing blood transfusions decreases
      inflammation and post-operative complications following open heart surgery.

      Conclusion: We believe that washing blood transfusions given to children following open
      heart surgery will decrease their inflammatory response and improve their overall health.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>12 Hour Plasma Interleukin (IL)-6 to IL-10 Ratio</measure>
    <time_frame>12 hours post-cardiopulmonary bypass</time_frame>
    <safety_issue>No</safety_issue>
    <description>plasma was obtained pre-op, immediately once off cardiopulmonary bypass (CPB), six hours following CPB and 12 hours following CPB. The plasma was centrifuged and the supernatant collected and stored at -70 degrees. The samples then underwent Luminex testing for IL-6 and IL-10 levels, and the IL-6:IL-10 ratio was calculated (IL-6 being the numerator and IL-12 being the denominator). The 12 hour ratio was the primary outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>wrCRP Levels</measure>
    <time_frame>days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Congenital Heart Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard leukoreduced irradiated blood cell transfusion group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Washed leukoreduced irradiated blood cell transfusion group</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Standard leukoreduced irradiated blood cell transfusion</intervention_name>
    <description>standard vs washed blood cell transfusions</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Washed leukoreduced irradiated blood cell transfusions</intervention_name>
    <description>washed leukoreduced irradiated blood cell transfusions</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age &lt; 18 years

          2. surgical repair at URMC by the pediatric cardiac surgical team

          3. informed consent signed by the parent or legal guardian, and if applicable, assent
             obtained from the subject.

        Exclusion Criteria:

          1. Age â‰¥18 years

          2. inability to provide consent/assent; 3) subjects having &quot;emergent&quot; surgical
             procedures. Subjects with chronic inflammatory or autoimmune disorders will not be
             excluded
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jill Cholette, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 28, 2012</lastchanged_date>
  <firstreceived_date>June 5, 2008</firstreceived_date>
  <firstreceived_results_date>November 30, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>jill cholette</investigator_full_name>
    <investigator_title>Assistant Professior</investigator_title>
  </responsible_party>
  <keyword>pediatrics</keyword>
  <keyword>congenital heart disease</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Potential subjects were recruited at pre-anesthesia inpatient assessments and outpatient pre-anesthesia appointments.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard Transfusion Group</title>
          <description>Standard leukoreduced irradiated ABO compatible red blood cell and platelet transfusion group</description>
        </group>
        <group group_id="P2">
          <title>Washed Transfusion Group</title>
          <description>Washed leukoreduced irradiated ABO compatible red blood cell and platelet transfusion group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Transfusion Group</title>
          <description>Standard leukoreduced irradiated ABO compatible red blood cell and platelet transfusion group</description>
        </group>
        <group group_id="B2">
          <title>Washed Transfusion Group</title>
          <description>Washed leukoreduced irradiated ABO compatible red blood cell and platelet transfusion group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="81"/>
                <measurement group_id="B2" value="81"/>
                <measurement group_id="B3" value="162"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="81"/>
                <measurement group_id="B2" value="81"/>
                <measurement group_id="B3" value="162"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <sub_title>Age</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1" lower_limit="1" upper_limit="17"/>
                <measurement group_id="B2" value="1" lower_limit="1" upper_limit="17"/>
                <measurement group_id="B3" value="1" lower_limit="1" upper_limit="17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="35"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="64"/>
                <measurement group_id="B2" value="63"/>
                <measurement group_id="B3" value="127"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>12 Hour Plasma Interleukin (IL)-6 to IL-10 Ratio</title>
        <description>plasma was obtained pre-op, immediately once off cardiopulmonary bypass (CPB), six hours following CPB and 12 hours following CPB. The plasma was centrifuged and the supernatant collected and stored at -70 degrees. The samples then underwent Luminex testing for IL-6 and IL-10 levels, and the IL-6:IL-10 ratio was calculated (IL-6 being the numerator and IL-12 being the denominator). The 12 hour ratio was the primary outcome measure.</description>
        <time_frame>12 hours post-cardiopulmonary bypass</time_frame>
        <safety_issue>No</safety_issue>
        <population>Only data from those subjects receiving transfusions was analyzed as the study intervention was the type of red blood cell and platelet transfusion (washed v. unwashed).</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Transfusion Group</title>
            <description>Standard leukoreduced irradiated ABO compatible red blood cell and platelet transfusion group</description>
          </group>
          <group group_id="O2">
            <title>Washed Transfusion Group</title>
            <description>Washed leukoreduced irradiated ABO compatible red blood cell and platelet transfusion group</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="64"/>
                  <measurement group_id="O2" value="64"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>12 Hour Plasma Interleukin (IL)-6 to IL-10 Ratio</title>
            <description>plasma was obtained pre-op, immediately once off cardiopulmonary bypass (CPB), six hours following CPB and 12 hours following CPB. The plasma was centrifuged and the supernatant collected and stored at -70 degrees. The samples then underwent Luminex testing for IL-6 and IL-10 levels, and the IL-6:IL-10 ratio was calculated (IL-6 being the numerator and IL-12 being the denominator). The 12 hour ratio was the primary outcome measure.</description>
            <units>ratio</units>
            <param>Median</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8.9" spread="1.2"/>
                  <measurement group_id="O2" value="3.8" spread="1.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>wrCRP Levels</title>
        <time_frame>days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Standard Transfusion Group</title>
          <description>Standard leukoreduced irradiated ABO compatible red blood cell and platelet transfusion group</description>
        </group>
        <group group_id="E2">
          <title>Washed Transfusion Group</title>
          <description>Washed leukoreduced irradiated ABO compatible red blood cell and platelet transfusion group</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="81"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jill M. Cholette MD, Principle Investigator</name_or_title>
      <organization>University of Rochester</organization>
      <phone>585-275-8138</phone>
      <email>Jill_Cholette@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
